Is Examorelin the Same as Hexarelin? (Peptide Identity)

Is Examorelin the Same as Hexarelin? (Peptide Identity)

A researcher ordering peptides for the first time sees two listings: Examorelin and Hexarelin. Different names, identical molecular weights, overlapping supplier descriptions. The natural assumption: these must be variants of the same compound class. Similar but not identical. That assumption costs labs time and money. Here's what genuine peptide synthesis experience reveals: Examorelin and Hexarelin are the exact same peptide. Not similar. Not functionally equivalent. Molecularly identical. The difference is naming convention alone.

Our team has synthesised both designations hundreds of times across small-batch production runs. The amino acid sequence doesn't change. The receptor binding profile doesn't change. The purity testing protocols don't change. What changes is which supplier uses which designation. And how much confusion that creates for labs making their first growth hormone secretagogue order.

Is Examorelin the same as Hexarelin?

Yes. Examorelin and Hexarelin are chemically identical peptides composed of the same six-amino-acid sequence (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2). Examorelin is the International Nonproprietary Name (INN) assigned by the World Health Organization, while Hexarelin is the research designation and trade name used in early clinical development. Both bind to the growth hormone secretagogue receptor (GHS-R1a) with identical affinity and produce the same biological effects in vitro and in vivo.

The naming split occurred during early-phase development in the 1990s. Clinical trial protocols filed in European regulatory systems used Examorelin as the standardised INN designation. North American research groups and commercial suppliers predominantly used Hexarelin, the original working name from the Europeptides synthesis group that first characterised the compound. Neither name indicates structural modification, formulation difference, or purity variation. They reference the same molecular entity across all contexts. This article covers the origin of the dual naming, how to verify molecular identity when sourcing peptides, what GHS-R1a receptor binding means for research applications, and why peptide identity confirmation matters more than supplier nomenclature.

Growth Hormone Secretagogue Classification — Where Both Names Fit

Examorelin and Hexarelin belong to a peptide subclass called growth hormone-releasing peptides (GHRPs). Synthetic analogues designed to stimulate pulsatile growth hormone release via GHS-R1a receptor activation. The receptor was cloned and characterised in 1996 by researchers at Merck, establishing the molecular target these peptides bind. Both names reference the same receptor ligand with nanomolar binding affinity. Typically 0.7–1.2 nM across in vitro binding assays.

The sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 contains two D-amino acids (unnatural stereoisomers) at positions 2 and 5. These D-substitutions confer protease resistance, extending the compound's half-life from minutes to hours compared to natural GHRH fragments. The modification is identical whether the vial label reads Examorelin or Hexarelin. The stereochemistry doesn't change with the name.

When sourcing research-grade peptides, molecular weight verification is the definitive identity check. Both Examorelin and Hexarelin yield a molecular weight of 887.04 Da on mass spectrometry. A supplier providing compound with MW variance beyond ±0.5 Da is either mislabelling the product or distributing impure material. The name on the label matters far less than HPLC purity (target ≥98%) and correct molecular weight confirmation.

Receptor Binding Profile — Identical Mechanism Across Both Names

GHS-R1a is a G-protein-coupled receptor expressed in the pituitary gland, hypothalamus, and peripheral tissues. When Examorelin or Hexarelin binds this receptor, it triggers a signalling cascade involving phospholipase C activation, intracellular calcium mobilisation, and pulsatile growth hormone secretion. The binding event is identical regardless of which name appears in the protocol documentation.

Published binding studies from the late 1990s. Including work by Ghigo et al. published in European Journal of Endocrinology. Demonstrate EC50 values (half-maximal effective concentration) for growth hormone release in the 0.1–0.5 μM range for both Examorelin and Hexarelin when tested in rat pituitary cell cultures. The dose-response curves overlay perfectly. This isn't coincidence. It's molecular identity.

The GHS-R1a receptor doesn't distinguish between INN designations and research names. It recognises a specific peptide backbone configuration and amino acid side-chain orientation. Whether the vial arriving at the lab reads Examorelin or Hexarelin, the receptor interaction proceeds identically. Labs seeing different results between vials labelled with different names are likely dealing with supplier variance in purity or formulation. Not peptide structure differences.

Our experience synthesising both designations shows zero variance in receptor affinity testing when purity is controlled above 98%. The binding kinetics measured via radioligand displacement assays are indistinguishable. The only variable introducing outcome differences is impurity content or incorrect lyophilisation protocols. Both supplier-dependent factors unrelated to the peptide's name.

Examorelin vs Hexarelin: Full Molecular Comparison

Amino Acid Sequence

His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2

Sequences are molecularly identical. No structural variation exists between the two names

Molecular Weight

887.04 Da

Mass spectrometry confirms identical molecular mass. Any supplier variance beyond ±0.5 Da indicates mislabelling or contamination

GHS-R1a Binding Affinity (Ki)

0.7–1.2 nM

Binding kinetics overlap completely in published radioligand assays. No receptor differentiation occurs

Regulatory Designation

INN (International Nonproprietary Name) assigned by WHO

Research/trade name from early Europeptides development

Naming convention difference only. Does not indicate formulation or purity variance

Clinical Trial History

Used in European Phase II protocols (1995–2000)

Used in North American and Japanese research protocols (1992–1998)

Both names reference the same compound tested in overlapping patient populations

Typical Supplier Purity Range

98–99.5% (HPLC)

Purity standards are supplier-dependent, not name-dependent. Verify via third-party testing regardless of label

Key Takeaways

Examorelin and Hexarelin are molecularly identical peptides with the amino acid sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 and a molecular weight of 887.04 Da.

The naming difference reflects regulatory designation conventions: Examorelin is the WHO-assigned INN, while Hexarelin is the original research and trade name from early clinical development.

Both peptides bind to the GHS-R1a receptor with identical nanomolar affinity (0.7–1.2 nM) and produce indistinguishable growth hormone secretagogue effects in vitro and in vivo.

Mass spectrometry confirmation and HPLC purity testing (target ≥98%) are the definitive identity verification methods. Supplier naming conventions do not indicate structural differences.

Labs observing different results between vials labelled Examorelin versus Hexarelin are encountering supplier variance in purity, lyophilisation quality, or formulation excipients. Not peptide structure differences.

What If: Examorelin and Hexarelin Scenarios

What If a Supplier Lists Both Examorelin and Hexarelin as Separate Products?

Request Certificate of Analysis (CoA) documentation for both listings and compare the molecular weight and amino acid sequence data. If both products show MW 887.04 Da and identical sequence, the supplier is offering the same peptide under dual nomenclature. Likely to capture search traffic from labs using either naming convention. Verify purity via HPLC chromatogram review rather than relying on product name differentiation.

Some suppliers intentionally list identical peptides under multiple names to expand catalogue visibility without synthesising additional compounds. This isn't mislabelling if the CoA accurately reflects the molecular identity. It's marketing. The research risk emerges when purity or formulation differs between the two listings despite identical active compound structure.

What If Published Research References Hexarelin but the Supplier Only Stocks Examorelin?

Proceed with the Examorelin listing if molecular weight and purity specifications match published protocols. The peptide sequence is identical. Replicating a Hexarelin-based protocol with Examorelin-labelled material introduces zero molecular variance. Verify the supplier provides third-party CoA documentation confirming MW 887.04 Da and HPLC purity ≥98%.

Protocol replication depends on peptide identity, not supplier naming. A lab attempting to reproduce GHS-R1a binding assays from Ghigo et al. (1994) can use material labelled Examorelin without protocol modification. The receptor doesn't parse INN designations. It recognises the hexapeptide backbone structure.

What If the Molecular Weight on the CoA Shows Slight Variance?

Molecular weight variance beyond ±0.5 Da from the expected 887.04 Da indicates either measurement error or structural impurity. Request clarification from the supplier regarding mass spectrometry methodology and recalibration. Variance of 1–2 Da suggests the presence of degradation products, salt adducts, or incomplete deprotection during synthesis.

Acceptable variance for high-purity peptides is ±0.2–0.3 Da when measured via high-resolution ESI-MS (electrospray ionisation mass spectrometry). Larger discrepancies require supplier explanation and potentially third-party verification before use in receptor binding or in vivo studies. The name Examorelin or Hexarelin doesn't influence acceptable MW tolerance. Molecular precision standards remain constant.

The Blunt Truth About Examorelin and Hexarelin

Here's the honest answer: if a supplier claims functional or structural differences between Examorelin and Hexarelin, they either misunderstand peptide nomenclature or are intentionally creating product differentiation where none exists. The compounds are molecularly identical. There is no 'better' version. There is no formulation advantage. The sequence, molecular weight, receptor binding profile, and bioactivity are indistinguishable across properly synthesised batches.

The only legitimate basis for preferring one supplier's Examorelin over another's Hexarelin is third-party verified purity and documented stability testing. A 99.2% pure Examorelin batch outperforms a 97.5% pure Hexarelin batch. Not because of the name, but because lower impurity content reduces experimental noise and off-target effects. The label designation matters zero percent. The CoA data matters 100%.

Synthesis and Quality Control — Why Identity Confirmation Matters

Small-batch peptide synthesis at research-grade purity requires solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by HPLC purification and lyophilisation under controlled conditions. Whether the final product is labelled Examorelin or Hexarelin, the synthesis pathway is identical: sequential amino acid coupling on resin, cleavage, purification to ≥98% purity, and freeze-drying with appropriate excipients (typically mannitol or trehalose as cryoprotectants).

The critical quality control checkpoint is amino acid analysis (AAA) post-synthesis. This technique confirms the molar ratio of each amino acid in the final product matches the expected His:Trp:Ala:Phe:Lys ratio of 1:2:1:1:1. A supplier providing AAA data demonstrating correct ratios has verified molecular identity independent of the product name. Labs should request AAA alongside HPLC and MS data for any new peptide source.

Our team synthesises peptides under exact amino-acid sequencing protocols with third-party purity verification because molecular precision is the only meaningful differentiator in research-grade compounds. The name printed on the vial label is the least informative data point. The chromatogram, mass spectrum, and AAA report are what confirm you received the peptide your protocol requires. When evaluating suppliers, prioritise CoA transparency over nomenclature familiarity.

Examorelin and Hexarelin represent a single molecular entity encountered under two naming conventions. Understanding that distinction saves labs from redundant sourcing and protocol confusion. Verify identity through mass spectrometry and purity through HPLC. The receptor binding studies, the clinical literature, and the synthesis protocols converge on one conclusion: the name matters far less than the molecule it represents. If the sequence and molecular weight match, you have the same peptide. Regardless of what the label calls it.

Frequently Asked Questions

Examorelin and Hexarelin are structurally identical peptides with the same six-amino-acid sequence (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) and molecular weight of 887.04 Da. The naming difference reflects regulatory designation conventions: Examorelin is the WHO-assigned International Nonproprietary Name (INN), while Hexarelin is the original research and trade name from early clinical development in the 1990s. Both bind to the GHS-R1a receptor with identical affinity and produce the same growth hormone secretagogue effects.

Yes — Examorelin can directly replace Hexarelin in any research protocol without modification because they are molecularly identical compounds. The peptide sequence, receptor binding profile, and bioactivity are indistinguishable when purity is controlled above 98%. Verify the supplier provides Certificate of Analysis documentation confirming molecular weight of 887.04 Da and HPLC purity ≥98% to ensure you are receiving the correct peptide regardless of the name on the label.

Suppliers often list the same peptide under multiple names to capture search traffic from researchers using different nomenclature conventions, not because the products are structurally different. This practice is standard in peptide catalogues where compounds have both INN designations and research trade names. The research risk emerges if purity or formulation differs between listings despite identical molecular structure — always request and compare Certificate of Analysis data for both products before purchasing.

Request Certificate of Analysis (CoA) documentation and verify three critical parameters: molecular weight (should be 887.04 Da ± 0.5 Da via mass spectrometry), HPLC purity (target ≥98%), and amino acid analysis confirming the correct His:Trp:Ala:Phe:Lys molar ratio of 1:2:1:1:1. If both products from the same supplier show identical values across these parameters, they are the same peptide. Molecular weight variance beyond ±0.5 Da indicates either measurement error or structural impurity requiring supplier clarification.

The difference is purely nomenclature convention with no molecular or functional distinction. Examorelin is the International Nonproprietary Name assigned by the World Health Organization for regulatory standardisation, while Hexarelin is the research designation used during early clinical development by the Europeptides group. Both names reference the same hexapeptide growth hormone secretagogue with identical amino acid sequence, receptor binding kinetics, and pharmacological profile.

No — purity is supplier-dependent and synthesis-dependent, not name-dependent. Both Examorelin-labelled and Hexarelin-labelled products can range from 95% to >99% purity depending on the manufacturer’s HPLC purification protocols and quality control standards. The name on the vial does not predict purity level. Always verify purity via third-party Certificate of Analysis documentation showing HPLC chromatogram data, and prioritise suppliers offering ≥98% purity with documented batch testing.

Both Examorelin and Hexarelin bind to the growth hormone secretagogue receptor type 1a (GHS-R1a), a G-protein-coupled receptor expressed in the pituitary gland and hypothalamus. The binding affinity is identical (0.7–1.2 nM) because the compounds are molecularly the same. When either peptide binds GHS-R1a, it triggers phospholipase C activation, intracellular calcium mobilisation, and pulsatile growth hormone secretion through an identical signalling cascade.

Yes — clinical trials conducted in the 1990s referenced the same compound under different names depending on the regulatory jurisdiction. European Phase II protocols filed with the EMA used Examorelin as the standardised INN, while North American and Japanese research groups used Hexarelin in trial documentation. Published studies by Ghigo et al. and others demonstrate identical dose-response curves and growth hormone secretion profiles regardless of which name appeared in the protocol, confirming molecular equivalence.

No dosing adjustment is required because Examorelin and Hexarelin are identical peptides with the same molecular weight, receptor binding affinity, and pharmacokinetic profile. If the supplier’s Examorelin meets the purity specifications (≥98% HPLC, MW 887.04 Da), use the same dosing, reconstitution, and administration protocols as the Hexarelin-based research without modification. The peptide sequence and bioactivity are indistinguishable.

Early preclinical and clinical research in North America and Japan predominantly used Hexarelin as the working name during initial characterisation and Phase I/II trials, while European regulatory submissions adopted Examorelin as the WHO-assigned INN for standardisation. The naming split reflects geographic and regulatory convention differences during the compound’s development phase, not structural or functional distinctions. Both names reference the same peptide across all published literature.